AgeneBio enrolls first patient in phase 3 trial for AGB101 in MCI due to Alzheimer’s Disease

AgeneBio, a leading biopharmaceutical company specialising in central nervous system (CNS) disorders, has announced the enrolment of the first patient in its pivotal phase 3 ... Read More